IcoSema, a combination therapy of basal insulin icodec and semaglutide, achieves a noninferior reduction in A1c levels compared with basal-bolus therapy in adults with T2D.

The addition of anagliptin to insulin and metformin therapy may improve glycemic control in patients with type 2 diabetes while maintaining an acceptable safety profile.

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with ...

Eli Lilly and Company (NYSE: LLY) today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials ...

Oral semaglutide was associated with more pronounced cardiovascular benefits among patients with higher baseline HbA1c in ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

In the realm of diabetes management and diagnosis, two tests often come into focus: the fasting glucose test and the A1c test. Both are crucial tools in assessing blood sugar levels, but they serve ...

LifeSouth Community Blood Centers is offering free A1c testing to blood donors until Sunday, August 31, providing an ...

I read your recent column on A1C levels. You said that 7% to 7.5% was ideal for most people. For older people, you said 8% can be good. My longstanding understanding of A1C levels is that less than 5.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.